F16.959

Clinical Causes: Use of hallucinogenic substances such as LSD, psilocybin, or mescaline, even without a confirmed substance use disorder Phencyclidine (PCP) or other dissociative drugs' use leading to psychotic symptoms Underlying mental health vulnerabilities that may be triggered by hallucinogen use

Key Symptoms: Auditory or visual hallucinations that are clearly perceptible to others Disorganized thinking and speech influencing the ability to communicate effectively Suspiciousness or paranoid delusions Emotional disturbances such as anxiety, fear, or agitation Altered perception of reality, often leading to confusion and impaired judgment Physical symptoms like dilated pupils, increased heart rate, or tremors during the episode Potential agitation or aggressive behavior depending on severity

Diagnosis Path: Diagnosis is typically based on a detailed clinical history and mental health evaluation, focusing on recent hallucinogen use and associated psychotic symptoms. No specific laboratory tests can confirm the disorder, but toxicology screenings may be used to detect recent drug use. Healthcare providers assess the timing, context, and presence of psychotic features to differentiate this disorder from other psychiatric or medical conditions.

Treatment Protocols: Management often involves a combination of approaches aimed at alleviating symptoms and preventing further episodes. This may include pharmacological interventions such as antipsychotics for acute psychosis, as well as supportive therapies that provide a safe environment. Addressing underlying substance use and offering psychoeducation or counseling are critical components of long-term care. In cases where the psychotic symptoms resolve after cessation of the hallucinogen, ongoing mental health support may still be necessary to monitor for recurrence or underlying psychiatric conditions.